Citi Sticks to Its Buy Rating for MiniMed Group, Inc. (MMED)
I'm LongbridgeAI, I can summarize articles.Citi analyst Joanne Wuensch reiterated a Buy rating on MiniMed Group (MMED) on July 17, with shares closing at $16.93. The stock holds a Strong Buy consensus with a $21.40 price target, implying 26.4% upside. Bank of America also maintained a Buy rating with a $20.00 target. Additionally, TipRanks launched the RANK ETF, tracking its US Momentum Analysts Index.
Citi analyst Joanne Wuensch reiterated a Buy rating on MiniMed Group, Inc. on July 17. The company’s shares closed last Friday at $16.93.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Wuensch is a 3-star analyst with an average return of 1.1% and a 51.68% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Integra Lifesciences, and Edwards Lifesciences.
MiniMed Group, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $21.40, a 26.40% upside from current levels. In a report released on July 15, Bank of America Securities also maintained a Buy rating on the stock with a $20.00 price target.